<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03418675</url>
  </required_header>
  <id_info>
    <org_study_id>17-1729</org_study_id>
    <nct_id>NCT03418675</nct_id>
  </id_info>
  <brief_title>Brexpiprazole in Borderline Personality Disorder</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Study of Brexpiprazole in the Treatment of Borderline Personality Disorder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka America Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the proposed study is to evaluate the safety and efficacy of
      Brexpiprazole in adults with borderline personality disorder (BPD). The hypothesis to be
      tested is that brexpiprazole will be more effective and well tolerated in adults with BPD
      compared to placebo. The proposed study will provide needed data on the treatment of a
      disabling disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Borderline personality disorder is characterized by mood instability, cognitive symptoms,
      impulsive behavior, and disturbed relationships (1-3). A variety of psychotherapies have been
      developed (4-6) and, while research on the use of medication is ongoing, no drug has been
      approved in the United States or elsewhere for its treatment (7). Second generation
      antipsychotics have been the most intensively studied (8-11). Current treatments for BPD are
      often inadequate. Dialectical behavioral therapy has been shown to reduce BPD but finding
      trained psychologists is difficult.

      Dysfunctions in the serotoninergic and dopaminergic systems have been demonstrated in—and
      considered as possible causes for—symptoms associated with the disorder (25-28). Several
      studies on the use of traditional (29) and atypical antipsychotic agents in patients with
      borderline personality disorder (30-31) have shown a positive effect on individual symptoms
      (29, 32-36). However, we are not aware of any study evaluating Brexpiprazole in the treatment
      of patients with borderline personality disorder. In the proposed double-blind,
      placebo-controlled study, the influence of Brexpiprazole on the multifaceted
      psychopathological symptoms and aggression of patients with borderline personality disorder
      will be investigated.

      Brexpiprazole therefore has distinctive properties that make it a promising option for
      patients with BPD. Brexpiprazole is a novel D2 partial agonist, has affinity for 5-HT1A, acts
      as an antagonist of the noradrenergic α1/2 receptor, partial agonist for D3, and antagonist
      for 5-HT2A (37-39). In addition, because of low rates of side effects, Brexpiprazole should
      be a well-tolerated and in fact desired medication approach to BPD.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Zanarini Rating Scale for Borderline Personality Disorder</measure>
    <time_frame>13 weeks</time_frame>
    <description>A clinician-administered scale assessing Borderline Personality Scale severity at all 9 visits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Overt Aggression Scale (MOAS)</measure>
    <time_frame>13 weeks</time_frame>
    <description>A clinician-administered behavior rating scale measuring four types of aggressive behavior that will be assessed at all 9 visits. The subsets range on a scale from 0-4 with 0 indicating no aggression present. This scale tracks changes in level of aggression over time. The total weighted sum of the sections of the scale is recorded. Higher total scores indicate higher aggression levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Young Mania Rating Scale</measure>
    <time_frame>13 weeks</time_frame>
    <description>A clinician-administered, 11 item scale that assesses manic symptoms at baseline and over time. Higher total scores indicate higher severity of manic symptoms. This scale is used to rate the severity of manic abnormality in the patient. Subsets of the scale range from 0-4 with 0 indicating no severity.This scale will be assessed at all 9 visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self report version of Zanarini Scale</measure>
    <time_frame>13 weeks</time_frame>
    <description>A self-report scale assessing Borderline Personality severity that will be assessed at all 9 visits.This scale is assessing severity and change in BPD symptoms. Scoring is done by counting the number of yes's. A score of 8 or more is indicative of a diagnosis of borderline personality disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borderline Evaluation of Severity Over Time (BEST)</measure>
    <time_frame>13 weeks</time_frame>
    <description>A self rated scale used to measure severity and change. The first 12 items of the scale are on a scale from 1-5, with 5 meaning that the item caused extreme distress, severe difficulties in relationships, and/or kept them from getting things done. The lowest rating (1) means it caused little or no problems. Items 13-15 (positive behaviors) are rated according to frequency. This scale will be assessed at all 9 visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barratt Impulsiveness Scale (BIS)</measure>
    <time_frame>13 weeks</time_frame>
    <description>A self-report assessment of impulsivity that will be assessed at baseline and visit 8. All items are added to result in a total score. Higher total scores indicate higher impulsiveness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Checklist-90 Revised</measure>
    <time_frame>13 weeks</time_frame>
    <description>An instrument that helps evaluate a broad range of psychological problems and symptoms of psychopathology. This will be assessed at baseline and visit 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Rating Scale (HAM-A)</measure>
    <time_frame>13 weeks</time_frame>
    <description>A clinician-administered assessment of anxiety that will be assessed at all 9 study visits. Changes in scores from baseline to final visit will be assessed. Higher scores indicate higher levels of anxiety, with 0 being no symptoms of anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale (HAM-D)</measure>
    <time_frame>13 weeks</time_frame>
    <description>A clinician-administered assessment of depression that will be assessed at all 9 study visits. Higher total scores indicate higher levels of depression, while a score of 0 would indicate no depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MINI International Neuropsychiatric Interview</measure>
    <time_frame>13 weeks</time_frame>
    <description>A short-structured interview that assesses psychiatric disorders according to the DSM V. This assessment will be done during the baseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Scale (SDS)</measure>
    <time_frame>13 weeks</time_frame>
    <description>Subjects will complete the SDS at all 9 visits. The change in scores from baseline to study completion will be assessed. The scale itself assesses the level of disability from borderline personality disorder (or target disorder) with higher scores indicating a more debilitating disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Inventory (QOLI)</measure>
    <time_frame>13 weeks</time_frame>
    <description>A self-report assessment of patient perceived quality of life that will be assessed at baseline and visit 8. Higher scores indicate a higher quality of life, whereas lower scores indicate a lower quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia Suicide Severity Rating Scale (CSSRS)</measure>
    <time_frame>13 weeks</time_frame>
    <description>A self-report scale measuring suicidality. Subjects will complete the scale at all 9 visits.Subjects are asked about suicidal thoughts. If answers are no, rater can proceed to &quot;suicidal behavior&quot; section where subject is asked about any non-suicidal self injurious behavior. If yes, subject is asked about intensity of ideations. In the event of serious threat to themselves, the subject will be escorted to the emergency room.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Borderline Personality Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 milligram per day for the first week and 1 milligram per day for the final taper week 2 milligrams per day for 10 weeks between taper periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rexulti</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 milligram per day day for the first week and 1 milligram per day for the final taper week 2 milligrams per day for 10 weeks between taper periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rexulti</intervention_name>
    <description>Atypical antipsychotic</description>
    <arm_group_label>Rexulti</arm_group_label>
    <other_name>Brexpiprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pill that contains no medicine</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women age 18-65;

          2. Primary diagnosis of BPD

          3. Zanarini scale score of at least 9 at baseline

          4. Ability to understand and sign the consent form.

        Exclusion Criteria:

          1. Unstable medical illness based on history or clinically significant abnormalities on
             baseline physical examination

          2. Subjects with schizophrenia or bipolar I disorder

          3. Subjects with an active substance use disorder

          4. Current pregnancy or lactation, or inadequate contraception in women of childbearing
             potential

          5. Subjects considered an immediate suicide risk based on the Columbia Suicide Severity
             rating Scale (C-SSRS) (www.cssrs.columbia.edu/docs)

          6. Illegal substance use based on urine toxicology screening

          7. Initiation of psychological interventions within 3 months of screening

          8. Use of any other psychotropic medication

          9. Previous treatment with Brexpiprazole

         10. Cognitive impairment that interferes with the capacity to understand and
             self-administer medication or provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon E Grant, JD, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Valle, BA</last_name>
    <phone>773-834-3778</phone>
    <email>valles@uchicago.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Redden, BA</last_name>
    <phone>773-702-9066</phone>
    <email>sredden@bsd.uchicago.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gunderson J: Borderline Personality Disorder, 2nd ed. Washington, DC, American Psychiatric Press, 2000</citation>
  </reference>
  <reference>
    <citation>Nakao K, Gunderson JG, Phillips KA, Tanaka N: Functional impairment in personality disorders. J Pers Disord 1992; 6:24-31</citation>
  </reference>
  <reference>
    <citation>Black DW, Blum N, Pfohl B, Hale N. Suicidal behavior in borderline personality disorder: prevalence, risk factors, prediction, and prevention. J Pers Disord. 2004 Jun;18(3):226-39. Review.</citation>
    <PMID>15237043</PMID>
  </reference>
  <reference>
    <citation>Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ, Heard HL, Korslund KE, Tutek DA, Reynolds SK, Lindenboim N. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry. 2006 Jul;63(7):757-66. Erratum in: Arch Gen Psychiatry. 2007 Dec;64(12):1401.</citation>
    <PMID>16818865</PMID>
  </reference>
  <reference>
    <citation>Blum N, St John D, Pfohl B, Stuart S, McCormick B, Allen J, Arndt S, Black DW. Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. Am J Psychiatry. 2008 Apr;165(4):468-78. doi: 10.1176/appi.ajp.2007.07071079. Epub 2008 Feb 15. Erratum in: Am J Psychiatry. 2008 Jun;165(6):777.</citation>
    <PMID>18281407</PMID>
  </reference>
  <reference>
    <citation>McMain SF, Guimond T, Streiner DL, Cardish RJ, Links PS. Dialectical behavior therapy compared with general psychiatric management for borderline personality disorder: clinical outcomes and functioning over a 2-year follow-up. Am J Psychiatry. 2012 Jun;169(6):650-61. doi: 10.1176/appi.ajp.2012.11091416.</citation>
    <PMID>22581157</PMID>
  </reference>
  <reference>
    <citation>Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry. 2010 Jan;196(1):4-12. doi: 10.1192/bjp.bp.108.062984. Review.</citation>
    <PMID>20044651</PMID>
  </reference>
  <reference>
    <citation>Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, Buschmann W, Rother N, Fartacek R, Egger C, Anvar J, Rother WK, Loew TH, Kaplan P. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006 May;163(5):833-8.</citation>
    <PMID>16648324</PMID>
  </reference>
  <reference>
    <citation>Schulz SC, Zanarini MC, Bateman A, Bohus M, Detke HC, Trzaskoma Q, Tanaka Y, Lin D, Deberdt W, Corya S. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry. 2008 Dec;193(6):485-92. doi: 10.1192/bjp.bp.107.037903.</citation>
    <PMID>19043153</PMID>
  </reference>
  <reference>
    <citation>Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D, Deberdt W, Kryzhanovskaya L, Corya S. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2011 Oct;72(10):1353-62. doi: 10.4088/JCP.08m04138yel.</citation>
    <PMID>21535995</PMID>
  </reference>
  <reference>
    <citation>Pascual JC, Soler J, Puigdemont D, Pérez-Egea R, Tiana T, Alvarez E, Pérez V. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry. 2008 Apr;69(4):603-8.</citation>
    <PMID>18251623</PMID>
  </reference>
  <reference>
    <citation>Rinne T, de Kloet ER, Wouters L, Goekoop JG, de Rijk RH, van den Brink W. Fluvoxamine reduces responsiveness of HPA axis in adult female BPD patients with a history of sustained childhood abuse. Neuropsychopharmacology. 2003 Jan;28(1):126-32.</citation>
    <PMID>12496948</PMID>
  </reference>
  <reference>
    <citation>Flewett T, Bradley P, Redvers A. Management of borderline personality disorder. Br J Psychiatry. 2003 Jul;183:78-9.</citation>
    <PMID>12835254</PMID>
  </reference>
  <reference>
    <citation>Verheul R, Van Den Bosch LM, Koeter MW, De Ridder MA, Stijnen T, Van Den Brink W. Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. Br J Psychiatry. 2003 Feb;182:135-40.</citation>
    <PMID>12562741</PMID>
  </reference>
  <reference>
    <citation>Nickel M, Nickel C, Leiberich P, Mitterlehner F, Forthuber P, Tritt K, Rother W, Loew T. [Psychosocial characteristics in persons who often change their psychotherapists]. Wien Med Wochenschr. 2004 Apr;154(7-8):163-9. German.</citation>
    <PMID>15182043</PMID>
  </reference>
  <reference>
    <citation>Nickel MK, Nickel C, Mitterlehner FO, Tritt K, Lahmann C, Leiberich PK, Rother WK, Loew TH. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry. 2004 Nov;65(11):1515-9.</citation>
    <PMID>15554765</PMID>
  </reference>
  <reference>
    <citation>Nickel MK, Nickel C, Kaplan P, Lahmann C, Mühlbacher M, Tritt K, Krawczyk J, Leiberich PK, Rother WK, Loew TH. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry. 2005 Mar 1;57(5):495-9.</citation>
    <PMID>15737664</PMID>
  </reference>
  <reference>
    <citation>MacKinnon DF, Zandi PP, Gershon E, Nurnberger JI Jr, Reich T, DePaulo JR. Rapid switching of mood in families with multiple cases of bipolar disorder. Arch Gen Psychiatry. 2003 Sep;60(9):921-8.</citation>
    <PMID>12963674</PMID>
  </reference>
  <reference>
    <citation>Crandell LE, Patrick MP, Hobson RP. 'Still-face' interactions between mothers with borderline personality disorder and their 2-month-old infants. Br J Psychiatry. 2003 Sep;183:239-47.</citation>
    <PMID>12948998</PMID>
  </reference>
  <reference>
    <citation>Lieb K, Zanarini MC, Schmahl C, Linehan MM, Bohus M. Borderline personality disorder. Lancet. 2004 Jul 31-Aug 6;364(9432):453-61. Review.</citation>
    <PMID>15288745</PMID>
  </reference>
  <reference>
    <citation>Frankenburg FR, Zanarini MC. The association between borderline personality disorder and chronic medical illnesses, poor health-related lifestyle choices, and costly forms of health care utilization. J Clin Psychiatry. 2004 Dec;65(12):1660-5.</citation>
    <PMID>15641871</PMID>
  </reference>
  <reference>
    <citation>Sher L, Oquendo MA, Li S, Huang YY, Grunebaum MF, Burke AK, Malone KM, Mann JJ. Lower CSF homovanillic acid levels in depressed patients with a history of alcoholism. Neuropsychopharmacology. 2003 Sep;28(9):1712-9. Epub 2003 Jun 25.</citation>
    <PMID>12825091</PMID>
  </reference>
  <reference>
    <citation>Yen S, Shea MT, Sanislow CA, Grilo CM, Skodol AE, Gunderson JG, McGlashan TH, Zanarini MC, Morey LC. Borderline personality disorder criteria associated with prospectively observed suicidal behavior. Am J Psychiatry. 2004 Jul;161(7):1296-8.</citation>
    <PMID>15229066</PMID>
  </reference>
  <reference>
    <citation>Zanarini MC, Frankenburg FR, Hennen J, Silk KR. The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. Am J Psychiatry. 2003 Feb;160(2):274-83.</citation>
    <PMID>12562573</PMID>
  </reference>
  <reference>
    <citation>Friedel RO. Dopamine dysfunction in borderline personality disorder: a hypothesis. Neuropsychopharmacology. 2004 Jun;29(6):1029-39. Review.</citation>
    <PMID>15039763</PMID>
  </reference>
  <reference>
    <citation>Hansenne M, Pitchot W, Pinto E, Reggers J, Scantamburlo G, Fuchs S, Pirard S, Ansseau M. 5-HT1A dysfunction in borderline personality disorder. Psychol Med. 2002 Jul;32(5):935-41.</citation>
    <PMID>12171388</PMID>
  </reference>
  <reference>
    <citation>Nickel M, Leiberich P, Mitterlehner F: Atypical neuroleptics in personality disorders. Psychodynamic Psychotherapy 2003; 2:25-32</citation>
  </reference>
  <reference>
    <citation>Soloff PH, George A, Nathan S, Schulz PM, Cornelius JR, Herring J, Perel JM. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol. 1989 Aug;9(4):238-46.</citation>
    <PMID>2768542</PMID>
  </reference>
  <reference>
    <citation>Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003 May 10;361(9369):1581-9. Review.</citation>
    <PMID>12747876</PMID>
  </reference>
  <reference>
    <citation>Pascual JC, Oller S, Soler J, Barrachina J, Alvarez E, Pérez V. Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services. J Clin Psychiatry. 2004 Sep;65(9):1281-2.</citation>
    <PMID>15367057</PMID>
  </reference>
  <reference>
    <citation>Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004 Jul;65(7):903-7.</citation>
    <PMID>15291677</PMID>
  </reference>
  <reference>
    <citation>Ferreri MM, Loze JY, Rouillon F, Limosin F. Clozapine treatment of a borderline personality disorder with severe self-mutilating behaviours. Eur Psychiatry. 2004 May;19(3):177-8. Erratum in: Eur Psychiatry. 2004 Sep;19(6):393. Ferrerri, MM [corrected to Ferreri, M].</citation>
    <PMID>15158928</PMID>
  </reference>
  <reference>
    <citation>Bogenschutz MP, George Nurnberg H. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004 Jan;65(1):104-9.</citation>
    <PMID>14744178</PMID>
  </reference>
  <reference>
    <citation>Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001 Nov;62(11):849-54.</citation>
    <PMID>11775043</PMID>
  </reference>
  <reference>
    <citation>Zanarini MC. Update on pharmacotherapy of borderline personality disorder. Curr Psychiatry Rep. 2004 Feb;6(1):66-70. Review.</citation>
    <PMID>14738708</PMID>
  </reference>
  <reference>
    <citation>Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mørk A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbøl TB, Kikuchi T. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014 Sep;350(3):589-604. doi: 10.1124/jpet.114.213793. Epub 2014 Jun 19.</citation>
    <PMID>24947465</PMID>
  </reference>
  <reference>
    <citation>Maeda K, Lerdrup L, Sugino H, Akazawa H, Amada N, McQuade RD, Stensbøl TB, Bundgaard C, Arnt J, Kikuchi T. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014 Sep;350(3):605-14. doi: 10.1124/jpet.114.213819. Epub 2014 Jun 19. Erratum in: J Pharmacol Exp Ther. 2014 Dec;351(3):686-7.</citation>
    <PMID>24947464</PMID>
  </reference>
  <reference>
    <citation>Yoon S, Jeon SW, Ko YH, Patkar AA, Masand PS, Pae CU, Han C. Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder: A Systematic Review and Meta-Analysis. J Clin Psychopharmacol. 2017 Feb;37(1):46-53. doi: 10.1097/JCP.0000000000000622. Review.</citation>
    <PMID>27941419</PMID>
  </reference>
  <reference>
    <citation>Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57. Review.</citation>
    <PMID>9881538</PMID>
  </reference>
  <reference>
    <citation>HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62.</citation>
    <PMID>14399272</PMID>
  </reference>
  <reference>
    <citation>HAMILTON M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-5.</citation>
    <PMID>13638508</PMID>
  </reference>
  <reference>
    <citation>Sheehan DV (1983). The Anxiety Disease. New York: Scribner's.</citation>
  </reference>
  <reference>
    <citation>Frisch MB, Cornell J, Villaneuva M (1993). Clinical validation of the Quality of Life Inventory: a measure of life satisfaction for use in treatment planning and outcome assessment. Psychol Assess. 4:92-101.</citation>
  </reference>
  <reference>
    <citation>Zanarini MC, Vujanovic AA, Parachini EA, Boulanger JL, Frankenburg FR, Hennen J. Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Pers Disord. 2003 Jun;17(3):233-42. Erratum in: J Personal Disord. 2003 Aug;17(4):1 p following 369.</citation>
    <PMID>12839102</PMID>
  </reference>
  <reference>
    <citation>Kay SR, Wolkenfeld F, Murrill LM. Profiles of aggression among psychiatric patients. I. Nature and prevalence. J Nerv Ment Dis. 1988 Sep;176(9):539-46.</citation>
    <PMID>3418327</PMID>
  </reference>
  <reference>
    <citation>Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978 Nov;133:429-35.</citation>
    <PMID>728692</PMID>
  </reference>
  <reference>
    <citation>Zanarini MC, Weingeroff JL, Frankenburg FR, Fitzmaurice GM. Development of the self-report version of the Zanarini Rating Scale for Borderline Personality Disorder. Personal Ment Health. 2015 Nov;9(4):243-9. doi: 10.1002/pmh.1302. Epub 2015 Jul 14.</citation>
    <PMID>26174588</PMID>
  </reference>
  <reference>
    <citation>Pfohl B, Blum N, St John D, McCormick B, Allen J, Black DW. Reliability and validity of the Borderline Evaluation of Severity Over Time (BEST): a self-rated scale to measure severity and change in persons with borderline personality disorder. J Pers Disord. 2009 Jun;23(3):281-93. doi: 10.1521/pedi.2009.23.3.281.</citation>
    <PMID>19538082</PMID>
  </reference>
  <reference>
    <citation>Barratt E: Anxiety and impulsiveness related to psychomotor efficiency. Percept Mot Skills 1959; 9:191-198</citation>
  </reference>
  <reference>
    <citation>Derogatis LR: SCL-90-R Administration, Scoring, and Procedures Manual II. Towson, Md, Clinical Psychometric Research, 1983</citation>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2018</study_first_submitted>
  <study_first_submitted_qc>January 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Chicago</investigator_affiliation>
    <investigator_full_name>Jon Grant</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brexpiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

